This is an aggregated industry headline. Read the full story at FierceBiotech →
Attovia files for IPO to take on Sanofi and Regeneron's Dupixent
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
By FierceBiotech
· Jul 15, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become…
The WeekSTAT News ↗
Blumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.…
The WeekBioPharma Dive ↗
Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier thi…